Nephrogenic Systemic Fibrosis is a man-made disease that was first recognized in 1997.

Originally called Nephrogenic Fibrosing Dermopathy, the cause of the illnes was unknown until recently. The development of Nephrogenic Systemic Fibrosis has been linked to the use of gadolinium-based contrast agents used in MRI procedures in patients with kidney failure.

According to the United States Food and Drug Administration, more than 215 cases of Nephrogenic Systemic Fibrosis linked with gadolinium-based contrast agents have been documented in the last 10 years. In 2006, the FDA published a report on the risks of gadolinium. In 2007, the agency issued a black box warning for gadolinium-based contrast agents, detailing the risks of NSF.

If you have developed NSF after being administered a gadolinium-based MRI contrast agent, please contact the Gadolinium Lawyers of Williams Kherkher by calling 800-761-3187.